HER3 as a determinant for the prognosis of melanoma

Details for Australian Patent Application No. 2009262420 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Ullrich, Axel; Knyazev, Pjotr; Reschke, Markus

Agent Peter Maxwell & Associates

Pub. Number AU-A-2009262420

PCT Pub. Number WO2009/156179

Priority 08011736.9 27.06.08 EP

Filing date 26 June 2009

Wipo publication date 30 December 2009

International Classifications

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

A61P 35/04 (2006.01) Antineoplastic agents

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/32 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

29 July 2010 PCT application entered the National Phase

  PCT publication WO2009/156179 Priority application(s): WO2009/156179

31 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009262422-Smoke-free cigarette

2009262418-Filter for a smoking article